Tesetaxel is a novel taxane with several properties that make it unique. In a multicenter, Phase 2 study, 38 HER2 negative, HR positive MBC patients receiving tesetaxel as a single agent achieved a confirmed ORR of 31% (12/38) and a median PFS of 6.8 months (95% CI 2.4 to 13.1). Treatment-related AEs were generally manageable. The primary efficacy endpoints are ORR and PFS for Cohort 1 and ORR for Cohort 2. The study provides important data on the efficacy and safety of tesetaxel in this patient population, demonstrating its potential as a treatment option for HER2 negative, HR positive MBC. Further research is needed to confirm these findings in larger, randomized trials.